Inpatient statin use predicts improved ischemic stroke discharge disposition

Neurology

Volumn 78, Issue 21, 2012, Pages 1678-1683

  Flint, A C ^a   Kamel, H ^b   Navi, B B ^c   Rao, V A ^a   Faigeles, B S ^a   Conell, C ^d   Klingman, J G ^a   Hills, N K ^c   Nguyen Huynh, M ^a,d   Cullen, S P ^a   Sidney, S ^d   Johnston, S C ^c,d  

^a KAISER PERMANENTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ADULT; ARTICLE; BRAIN ISCHEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK; STROKE PATIENT;

EID: 84863610017     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182575142     Document Type: Article

References (42)

1. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: A meta-analysis involving 121,000 patients. Am J Med 2008;121:24-33.
2. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: A network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52: 1769-1781.
3. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
4. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46:1855-1862.
5. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109(suppl 1):III39-II43.
6. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359: 2195-2207.
7. Mach F. Statins as immunomodulatory agents. Circulation 2004;109(suppl 1):II15-I17.
8. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-1278.
9. Lee K-T, Lai W-T, Chu C-S, et al. Effect of withdrawal of statin on C-reactive protein. Cardiology 2004;102:166-170.
10. Chen H, Ren J-Y, Xing Y, et al. Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: A dose-response effect dependent on endothelial nitric oxide synthase. Int J Cardiol 2009;131:313-320.
11. Sposito AC, Carvalho LSF, Cintra RMR, et al. Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. Atherosclerosis 2009;207:191-194.
12. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105:1446-1452.
13. Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: The GRACE study. Ann Intern Med 2004;140:857-866.
14. Spencer FA, Fonarow GC, Frederick PD, et al. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction. Arch Intern Med 2004;164:2162-2168.
15. Le Manach Y, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 2007;104:1326-1333.
16. Schouten O, Hoeks SE, Welten GMJM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007;100:316-320.
17. Flint AC, Kamel H, Navi BB, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke 2012;43:147-154.
18. Yeh P-S, Lin H-J, Bai C-H, Hsieh F-I, Ke D-S, Li Y-H. Effect of in-hospital initiation of lipid-lowering therapy on six-month outcomes in patients with acute ischemic stroke or transient ischemic attack. Am J Cardiol 2010;105: 1490-1494.
19. Milionis HJ, Giannopoulos S, Kosmidou M, et al. Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival. Neurology 2009;72:1816-1822.
20. Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007;38:2652-2657.
21. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: A controlled randomized study. Neurology 2007;69:904-910.
22. Johnston SC, Henneman T, McCulloch CE, van der Laan M. Modeling treatment effects on binary outcomes with grouped-treatment variables and individual covariates. Am J Epidemiol 2002;156:753-760.
23. Gillum LA, Johnston SC. Influence of physician specialty on outcomes after acute ischemic stroke. J Hosp Med 2008;3:184-192.
24. Rassen JA, Mittleman MA, Glynn RJ, Alan Brookhart M, Schneeweiss S. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J 2010;31:561-572.
25. Brookhart MA, Rassen JA, Wang PS, Dormuth C, Mogun H, Schneeweiss S. Evaluating the validity of an instrumental variable study of neuroleptics: Can between-physician differences in prescribing patterns be used to estimate treatment effects? Med Care 2007;45(suppl 2):S116-S122.
26. Ifejika-Jones NL, Harun N, Mohammed-Rajput NA, Noser EA, Grotta JC. Thrombolysis with intravenous tissue plasminogen activator predicts a favorable discharge disposition in patients with acute ischemic stroke. Stroke 2011;42:700-704.
27. Mishra NK, Shuaib A, Lyden P, et al. Home time is extended in patients with ischemic stroke who receive thrombolytic therapy: A validation study of home time as an outcome measure. Stroke 2011;42:1046-1050.
28. Mauthe RW, Haaf DC, Hayn P, Krall JM. Predicting discharge destination of stroke patients using a mathematical model based on six items from the Functional Independence Measure. Arch Phys Med Rehabil 1996;77:10-13.
29. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
30. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
31. Aslanyan S, Weir CJ, McInnes GT, Reid JL, Walters MR, Lees KR. Statin administration prior to ischaemic stroke onset and survival: Exploratory evidence from matched treatment-control study. Eur J Neurol 2005;12:493-498.
32. Elkind MSV, Flint AC, Sciacca RR, Sacco RL. Lipidlowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 2005;65:253-238.
33. Greisenegger S, Müllner M, Tentschert S, Lang W, Lalouschek W. Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 2004;221:5-10.
34. Martí-Fàbregas J, Gomis M, Arboix A, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004;35:1117-1121.
35. Arboix A, García-Eroles L, Oliveres M, Targa C, Balcells M, Massons J. Pretreatment with statins improves early outcome in patients with first-ever ischaemic stroke: A pleiotropic effect of statins or a beneficial effect of hypercholesterolemia? BMC Neurol 2010;10:47.
36. Biffi A, Devan WJ, Anderson CD, et al. Statin treatment and functional outcome after ischemic stroke: Case-control and meta-analysis. Stroke 2011;42:1314-1319.
37. Goldstein LB, Amarenco P, Zivin J, et al. Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke Epub 2009 Sep 10.
38. Gertz K, Laufs U, Lindauer U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003;34:551-557.
39. del Zoppo GJ. The neurovascular unit in the setting of stroke. J Intern Med 2010;267:156-171.
40. del Zoppo GL. Stroke and neurovascular protection. N Engl J Med 2006;354:553-555.
41. Endres M. Statins and stroke. J Cereb Blood Flow Metab 2005;25:1093-1110.
42. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559.